First-Line Pembrolizumab in PD-L1 Positive Non-Small Cell Lung Cancer- A Cost-Effectiveness Analysis from A UK Healthcare Perspective
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.006
https://www.valueinhealthjournal.com/article/S1098-3015(17)30339-X/fulltext
Title :
First-Line Pembrolizumab in PD-L1 Positive Non-Small Cell Lung Cancer- A Cost-Effectiveness Analysis from A UK Healthcare Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30339-X&doi=10.1016/j.jval.2017.08.006
First page :
A399
Section Title :
BREAKOUT SESSION I
Open access? :
No
Section Order :
4